Qiagen CFO Sees COVID Diagnostics Volatility Continuing In 2022
Executive Summary
Qiagen’s doubled-down focus on PCR technologies in late 2019 proved to be fortuitous, but future growth will come from many other drivers, says CFO Roland Sackers.
You may also be interested in...
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
DTx And Drug Deal Sees Closed Loop Medicine And Teva Team Up On Precision Care
Medicines are still typically prescribed based on average effects in a population and rarely dose-optimized for the individual, says Closed Loop Medicine. The company sees a new strategic partnership with Teva UK as another step in advancing personalized medicine.
Swiss-EU Standoff Set To End? Medtechs Eye MRA Action
Negotiations aimed at renewing the close trading relationship and barrier-free mutual market access between Switzerland and the EU got underway on 19 March. Swiss medtech companies welcomed the move, stressing the need for the defunct mutual recognition agreement to be updated.